1. Young RR. Spasticity: a review. Neurology 1994;44:S12-20.
2. Rice GP. Pharmacotherapy of spasticity: some theoretical and practical considerations. Can J Neurol Sci 1987;14:510-512.
3. Davidoff RA. Antispasticity drugs: mechanisms of action. Ann Neurol 1985;17:107-116.
4. Zafonte R, Lombard L, Elovic E. Antispasticity medications: uses and limitations of enteral therapy. Am J Phys Med Rehabil 2004;83:S50-58.
5. Bes A, Eyssette M, Pierrot?Deseilligny E, Rohmer F, Warter JM. A multi?centre, double?blind trial of tizanidine, a new antispastic agent, in spasticity associated with hemiplegia Curr Med Res Opin 1988;10:709-718.
6. Eyssette M, Rohmer F, Serratrice G, Warter JM, Boisson D. Multi?centre, double?blind trial of a novel antispastic agent, tizanidine, in spasticity associated with multiple sclerosis Curr Med Res Opin 1988;10:699-708.
7. Nance PW, Bugaresti J, Shellenberger K, Sheremata W, Mar-tinez?Arizala A. Efficacy and safety of tizanidine in the treatment of spasticity in patients with spinal cord injury. North American Tizanidine Study Group. Neurology 1994;44((11 Suppl 9):): S44-51;discussion. S51-52.
8. Coward DM. Tizanidine: neuropharmacology and mechanism of action. Neurology 1994;44((11 Suppl 9):): S6-10;discussion. S10-11.
9. Delwaide PJ, Pennisi G. Tizanidine and electrophysiologic analysis of spinal control mechanisms in humans with spasticity. Neurology 1994;44((11 Suppl 9):): S2-27;discussion. S27-28.
12. Donovan WH, Carter RE, Rossi CD, Wilkerson MA. Clonidine effect on spasticity: a clinical trial. Arch Phys Med Rehabil 1988;69((3 pt 1):193-194.
13. Herman R, Mayer N, Mecomber SA. Clinical pharmaco? physiology of dantrolene sodium Am J Phys Med 1972;51:296-311.
14. Flewellen EH, Nelson TE, Jones WP, Arens JF, Wagner DL. Dantrolene dose response in awake man: implications for management of malignant hyperthermia. Anesthesiology 1983;59:275-280.
15. Bishop B. Spasticity: its physiology and management. Part IV. Current and projected treatment procedures for spasticity. Phys Ther 1977;57:396-401.
16. Lin JP, Brown JK, Brotherstone R. Assessment of spasticity in hemiplegic cerebral palsy. II: Distal lower?limb reflex excitability and function Dev Med Child Neurol 1994;36:290-303.
17. Little J. Spasticity and associated abnormality of muscle tone. In: DeLIsa J, editor. Rehabilitation Medicine: Principles and Practice. 3rd ed.. Philadelphia: Lippincott?Raven; 2006. p. 997-1013.
18. Burke D. Spasticity as an adaptation to pyramidal tract injury. Adv Neurol 1988;47:401-423.
21. Utili R, Boitnott JK, Zimmerman HJ. Dantrolene?associated hepatic injury. Incidence and character Gastroenterology 1977;72:610-616.
22. Pinder RM, Brogden RN, Speight TM, Avery GS. Dantrolene sodium: a review of its pharmacological properties and therapeutic efficacy in spasticity. Drugs 1977;13:3-23.
23. Terrence CF, Fromm GH. Complications of baclofen withdrawal. Arch Neurol 1981;38:588-589.
24. Duncan GW, Shahani BT, Young RR. An evaluation of baclofen treatment for certain symptoms in patients with spinal cord lesions. A double?blind, cross? over study Neurology 1976;26:441-446.
25. Taricco M, Adone R, Pagliacci C, Telaro E. Pharmacological interventions for spasticity following spinal cord injury. Cochrane Database Syst Rev 2000;2:CD001131.
26. Gracies JM, Nance P, Elovic E, McGuire J, Simpson DM. Traditional pharmacological treatments for spasticity. Part II: General and regional treatments. Muscle Nerve Suppl 1997;6:S92-120.
27. Stahl MM, Saldeen P, Vinge E. Reversal of fetal benzodia-zepine intoxication using flumazenil. Br J Obstet Gynaecol 1993;100:185-188.
28. Nance P. Spasticity management. In: RL Braddom, editor. Physical Medicine and Rehabilitation. 3rd ed.. China: Saunders Elsevier; 2006. p. 651-665.
29. Roussan M, Terrence C, Fromm G. Baclofen versus diazepam for the treatment of spasticity and long?term follow?up of baclofen therapy Pharmatherapeutica 1985;4:278-284.
30. Dunevsky A, Perel AB. Gabapentin for relief of spasticity associated with multiple sclerosis. Am J Phys Med Rehabil 1998;77:451-454.
31. Basmajian JV, Shankardass K, Russell D, Yucel V. Ketazolam treatment for spasticity: double?blind study of a new drug Arch Phys Med Rehabil 1984;65:698-701.
32. Cendrowski W, Sobczyk W. Clonazepam, baclofen and placebo in the treatment of spasticity. Eur Neurol 1977;16:257-262.
33. Smolenski C, Muff S, Smolenski?Kautz S. A double?blind comparative trial of new muscle relaxant, tizanidine(DS 103-282), and baclofen in the treatment of chronic spasticity in multiple sclerosis Curr Med Res Opin 1981;7:374-383.
34. Medici M, Pebet M, Ciblis D. A double?blind, long?term study of tizanidine ('Sirdalud') in spasticity due to cerebrovascular lesions Curr Med Res Opin 1989;11:398-407.
35. Weingarden SI, Belen JG. Clonidine transdermal system for treatment of spasticity in spinal cord injury. Arch Phys Med Rehabil 1992;73:876-877.
36. Stewart JE, Barbeau H, Gauthier S. Modulation of locomotor patterns and spasticity with clonidine in spinal cord injured patients. Can J Neurol Sci 1991;18:321-332.
37. Dall JT, Harmon RL, Quinn CM. Use of clonidine for treatment of spasticity arising from various forms of brain injury: a case series. Brain Inj 1996;10:453-458.
38. Mandac BR, Hurvitz EA, Nelson VS. Hyperthermia associated with baclofen withdrawal and increased spasticity. Arch Phys Med Rehabil 1993;74:96-97.
39. Joynt RL, Leonard JA Jr. Dantrolene sodium suspension in treatment of spastic cerebral palsy. Dev Med Child Neurol 1980;22:755-767.